Aeolus Pharmaceuticals (AOLS) Stock Price, News & Analysis

Company Overview

Aeolus Pharmaceuticals, Inc. is a biotechnology company focused on developing medical countermeasures for diseases and injuries associated with oxidative stress, inflammation and exposure to chemical, biological or radiological threats. The company’s research has centered on synthetic antioxidant compounds designed to help protect tissue from damage caused by reactive oxygen species.

Its best-known development programs included AEOL 10150, an antioxidant enzyme mimetic investigated for conditions such as radiation-induced lung injury and other pulmonary disorders. Aeolus also studied related compounds, including AEOL 10123, for potential applications involving neurological and inflammatory diseases. The company’s programs were largely research-stage and included work supported by or conducted in collaboration with U.S. government agencies.

Aeolus Pharmaceuticals was a U.S.-based developer whose activities primarily involved pharmaceutical research and development rather than commercial product sales. Publicly available information about its current operations, commercial products and leadership is limited, and the company does not appear to have an established portfolio of marketed therapies.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 8/14/2017
• Today: 11/03/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:AOLS
• CIK: 1261734
• Web: www.aeoluspharma.com
• Phone: (949) 481-9825
• Fax: 949-481-9829
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A